author-photo

Albert Candia

University of California, Berkeley

15

Papers

517

Citations

Citation Trend

Filter By

Papers (10) Sort By

Journal Conference Others

Phase 1b/2, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (19)
Abstract CT224: Phase Ib/II, open label, multicenter study of inhaled DV281, a Toll-like receptor 9 agonist, in combination with nivolumab in patients with advanced or metastatic non small cell lung cancer (NSCLC)

2019 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (2)
Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced/metastatic melanoma resistant to anti-PD-1/PD-L1 therapy.

2019 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (4)
In Situ Vaccination with a TLR9 Agonist and Local Low-Dose Radiation Induces Systemic Responses in Untreated Indolent Lymphoma

2018 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (73)
SD-101 in Combination with Pembrolizumab in Advanced Melanoma: Results of a Phase Ib, Multicenter Study

2018 Cancer Discovery
Show All
- Source
- Cite
- Save
Citations (127)
Abstract LB-239: Pharmacodynamic changes confirm the mechanism of action mediating SD-101 efficacy, in combination with pembrolizumab, in a phase 1b/2 study in metastatic melanoma (MEL-01)

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT047: SD-101, a novel intratumoral class C CpG-ODN, given with low-dose radiation in patients with untreated low-grade B-cell lymphoma: interim results of a phase I trial

2016 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)
Hepatocyte mitochondrial DNA drives nonalcoholic steatohepatitis by activation of TLR9

2016 Journal of Clinical Investigation
Show All
- Source
- Cite
- Save
Citations (245)
SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial

2016 Blood
Show All
- Source
- Cite
- Save
Citations (6)
237 Humans and Mice With NASH Have Increased Plasma Levels of TLR9 Ligand, and a TLR7/9 Bifunctional Antagonist Reduces NASH in Mice

2015 Gastroenterology
Show All
- Source
- Cite
- Save
Citations (0)